The NLRP3 inflammasome as a dynamic context-dependent regulator: mechanisms, disease progression, and therapeutic implications

Abstract

The NLRP3 inflammasome is a central regulator of innate immunity and inflammation, but its functions extend beyond a simple pro-inflammatory role. Increasing evidence indicates that the biological consequences of NLRP3 activation are highly context-dependent, with protective or pathogenic effects determined by cellular composition, tissue microenvironment, and disease stage. In this review, we examine NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts. We further discuss three major determinants of NLRP3 output: cytokine bias between IL-1β and IL-18, cell-fate decisions between pyroptosis and survival, and epigenetic programming of inflammasome-responsive states. Using representative disease settings such as cancer, inflammatory bowel disease, and autoimmune disorders, we illustrate how similar NLRP3 activation can lead to divergent biological outcomes. We also discuss the therapeutic implications of this plasticity, arguing that effective intervention will require context-selective rather than universal inhibition. A more precise understanding of NLRP3 context dependence may support rational trial design, biomarker development, future patient-stratification frameworks, and more biologically informed therapeutic strategies in NLRP3-related diseases.

Graphical Abstract

Introduction

NLRP3 inflammasome: structure and assembly

The NLRP3 protein is a 1036-amino acid cytoplasmic pattern recognition receptor belonging to the NOD-like receptor (NLR) family. Its tripartite structure consists of: (1) an N-terminal Pyrin domain (PYD) mediating protein-protein interactions during inflammasome assembly; (2) a central NACHT domain (nucleotide-binding and oligomerization domain) enabling ATP-dependent oligomerization upon activation; and (3) a C-terminal leucine-rich repeat (LRR) domain involved in autoinhibition and signal responsiveness [1, 2]. Specifically, the PYD mediates homotypic PYD–PYD interactions with ASC to initiate adaptor recruitment, whereas the NACHT domain drives ATP-dependent conformational change and oligomerization of NLRP3 molecules, thereby providing the structural platform for ASC speck formation and subsequent pro-caspase-1 activation.

Upon detecting cellular stress signals, NLRP3 recruits the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), which bridges NLRP3 to pro-caspase-1 through domain interactions. This proximity-induced activation generates active caspase-1, which processes pro-IL-1β and pro-IL-18 into mature cytokines and cleaves gasdermin D (GSDMD) to trigger pyroptosis [2, 3]. This classical pathway establishes NLRP3 as a key guardian of cellular stress and tissue damage.

Tissue distribution and cellular expression patterns

NLRP3 exhibits widespread but cell-type-specific expression patterns. At the tissue level, NLRP3 is most prominently detected in immune-related and barrier-associated organs, including the bone marrow, spleen, lymph nodes, lung, intestine, and brain [4]. Within these tissues, NLRP3 is predominantly enriched in myeloid lineages—monocytes, macrophages, neutrophils, and dendritic cells—where it functions as a frontline sensor for pathogen invasion and tissue damage [5, 6].

Single-cell profiling reveals heterogeneous expression even within myeloid populations, with tissue-resident macrophage subsets (alveolar, intestinal lamina propria) displaying higher basal levels than circulating monocytes [7]. Expression in non-immune cells (epithelial, endothelial, fibroblasts) remains debated, with concerns about contamination from infiltrating immune cells [8]. Importantly, NLRP3 protein levels are markedly upregulated by priming signals (LPS, TNF-α) through NF-κB-dependent transcription, a prerequisite for subsequent inflammasome activation [9, 10].

Pathophysiological roles: beyond simple inflammation

NLRP3’s physiological roles extend far beyond simple inflammation. In acute infections, NLRP3 activation promotes IL-1β-mediated fever and neutrophil recruitment, IL-18-driven interferon-γ production, and pathogen elimination through pyroptosis [11, 12]. Genetic studies confirm its protective role against bacterial (Staphylococcus aureus, Streptococcus pneumoniae), viral (influenza), and fungal (Candida albicans) challenges, with NLRP3-deficient mice showing increased susceptibility [13].

However, chronic NLRP3 activation in sterile inflammatory diseases—type 2 diabetes, obesity, atherosclerosis, neurodegenerative conditions, and autoinflammatory syndromes—drives maladaptive inflammation that exacerbates pathology [14, 15]. This duality represents the first level of context dependence: protective in acute infections, pathogenic in chronic sterile inflammation.

Scope of this review: a three-dimensional framework

The traditional view of NLRP3 as a uniformly pro-inflammatory and pathogenic mediator is no longer sufficient. Emerging evidence indicates that NLRP3 displays marked functional plasticity, and that its biological effects are strongly shaped by cellular context, microenvironmental context, and disease stage [16–18]. The same signaling machinery may protect tissue integrity in one setting while aggravating pathology in another. For example, in cancer, NLRP3 has been reported to suppress early tumor development through pyroptotic elimination of premalignant cells, yet to promote tumor progression in established disease through chronic IL-1β-driven inflammation [19–21]. Likewise, in inflammatory bowel disease, excessive IL-1β production during acute flares can exacerbate mucosal injury, whereas NLRP3-associated IL-18 signaling may preserve epithelial barrier integrity and support tissue repair.

This context dependence presents both a conceptual challenge and a translational opportunity. Mechanistically, it raises a central question: why can apparently similar NLRP3 activation generate opposite functional outcomes? Addressing this question requires attention to the molecular determinants that shape NLRP3 output in specific biological settings. Therapeutically, it suggests that NLRP3 should not be approached as a target for indiscriminate inhibition. Instead, intervention strategies must consider disease type, disease stage, cellular source, and local microenvironment.

In this review, we organize current evidence into three interconnected dimensions. First, we examine cellular context, focusing on how NLRP3 function differs across immune and non-immune cell populations. Second, we address microenvironmental context, including infectious versus sterile stimuli and pro-inflammatory versus tissue-repairing conditions. Third, we discuss disease context, emphasizing how NLRP3 function shifts across pathological settings and along disease progression. By integrating mechanistic insight, representative disease examples, and emerging clinical evidence, we aim to provide a framework for understanding when NLRP3 acts as a protective mediator, when it becomes pathogenic, and how this distinction may guide more rational therapeutic development.

Mechanistic determinants of context-dependent outcomes

Cytokine product bias and multi-output inflammasome signaling

A critical determinant of the functional outcome of NLRP3 activation is the relative balance between IL-1β and IL-18 production. Although both cytokines are processed by caspase-1, they often exert distinct, and sometimes opposing, biological effects [22–24]. IL-1β is a potent pro-inflammatory mediator that promotes fever, neutrophil recruitment, and amplification of innate immune responses through the induction of secondary inflammatory mediators such as prostaglandins, chemokines, and acute-phase proteins [25, 26]. By contrast, IL-18 has a more context-dependent role. In some settings, it acts together with IL-12 to promote Th1 differentiation and interferon-γ production, whereas in others it supports epithelial barrier integrity and tissue repair, particularly in the intestinal mucosa [27]. Importantly, the biological consequences of NLRP3 activation may depend less on the absolute abundance of either cytokine than on the relative IL-1β/IL-18 output profile, because IL-1β-dominant responses generally amplify inflammatory recruitment and tissue damage, whereas IL-18-dominant responses may support barrier integrity, epithelial repair, or Th1 immunity depending on the disease context.

However, the IL-1β/IL-18 ratio should be viewed as an organizing readout rather than a complete representation of NLRP3 output. NLRP3 activation can simultaneously generate multiple downstream signals, including ASC speck formation or release, inflammasome-complex assembly, GSDMD cleavage and pore formation, pyroptosis or hyperactivation, non-canonical caspase activation, and broader inflammatory or metabolic outputs such as DAMP release, mitochondrial stress, and metabolic remodeling [28–30]. These concurrent outputs may modify, amplify, or even override the biological consequences predicted by cytokine balance alone. Therefore, the IL-1β/IL-18 axis provides a useful but incomplete framework and should be interpreted together with broader inflammasome-related functional readouts.

Several factors help determine this cytokine bias. First, pro-IL-1β is tightly regulated at the transcriptional level and usually requires NF-κB-dependent priming, whereas pro-IL-18 is constitutively expressed in many cell types [31]. As a result, in the absence of strong priming signals, NLRP3 activation may preferentially yield IL-18-dominant output. Second, the kinetics and magnitude of caspase-1 activation may shape substrate processing: sustained and robust caspase-1 activation favors efficient cleavage of both pro-IL-1β and pro-IL-18, whereas weaker or transient activation may preferentially process the more readily available pro-IL-18. Third, cell-intrinsic features, including relative substrate abundance and differences in cytokine-processing capacity, may further shape cytokine output [32]. For example, in intestinal macrophages during chronic inflammation, epigenetic repression of IL1B may shift NLRP3 signaling toward IL-18, thereby converting a potentially tissue-damaging inflammatory response into a barrier-protective program [33, 34]. Together, these observations indicate that cytokine output is not a fixed property of the NLRP3 inflammasome itself, but rather an emergent consequence of cellular programming and environmental context.

Cell fate decisions: pyroptosis versus survival

In addition to shaping cytokine output, NLRP3 activation can also determine cell fate through caspase-1-mediated cleavage of gasdermin D (GSDMD), which may trigger pyroptotic cell death. Pyroptosis is a lytic and inflammatory form of programmed cell death characterized by membrane permeabilization, cell swelling, and release of intracellular contents, including IL-1β, IL-18, and damage-associated molecular patterns (DAMPs), thereby further amplifying local inflammation [34–36]. However, NLRP3 activation does not uniformly lead to pyroptosis in all cell types. Neutrophils, for example, often preferentially undergo NETosis rather than classical pyroptosis after inflammasome activation, and in some contexts this process involves caspase-11 in mice or caspase-4/5 in humans rather than caspase-1 [37]. This distinction has important functional consequences. Pyroptotic death of pathogen-containing macrophages may help eliminate intracellular infection, but it can also intensify tissue injury by releasing inflammatory mediators. By contrast, survival with continued cytokine secretion may preserve antimicrobial activity while limiting cell loss.

The balance between pyroptosis and survival is shaped by multiple factors. First, susceptibility to pyroptosis varies across cell types; some non-immune cells express low levels of GSDMD and may therefore resist pyroptotic death despite upstream inflammasome activation. Second, competing cell-death regulatory pathways can modify the outcome. In certain dendritic cell subsets, for example, caspase-8-mediated regulation of cell-death signaling may restrain excessive inflammatory death and favor functional preservation [38–40]. Third, membrane repair mechanisms are increasingly recognized as important determinants of post-activation fate. Cells with efficient ESCRT-dependent membrane repair machinery may repair GSDMD-induced membrane damage, survive the initial insult, and continue to secrete IL-1β and IL-18 without undergoing full lysis [41]. This sublytic state, often termed hyperactivation, refers to inflammasome-activated cells that remain viable despite gasdermin pore formation and sustain cytokine release without immediate pyroptotic death. It may be particularly relevant in chronic inflammatory settings, where persistent cytokine production without overt cell loss can sustain tissue inflammation over time.

Regulatory molecules with context-dependent roles

An additional layer of complexity in NLRP3 biology lies in the fact that certain regulatory molecules can function as either inhibitors or facilitators depending on cellular context. Caspase-8 is a representative example. In dendritic cells, caspase-8 can restrain NLRP3 activation by limiting excessive inflammatory signaling, thereby helping preserve immune tolerance and preventing uncontrolled inflammasome activity [42–44]. In contrast, in macrophages and other inflammatory cell types, caspase-8 may support NLRP3 priming by enhancing NF-κB activation and promoting pro-IL-1β transcription. Thus, the functional effect of caspase-8 is not fixed, but depends on the cellular program in which it operates.

A similar context dependence applies to post-translational regulation of NLRP3. Ubiquitination, for example, can either suppress or promote inflammasome activation depending on the specific ubiquitin ligase involved, the type of ubiquitin modification, and the lysine residues targeted [45]. Several E3 ligases, including MARCH7 and FBXL2, promote NLRP3 degradation and thereby limit inflammasome activity, whereas deubiquitinases such as BRCC3 stabilize NLRP3 and facilitate activation [22]. The net outcome of these opposing regulatory inputs is likely to vary across cell types and inflammatory states. Together, these observations indicate that NLRP3 regulation is not governed by uniformly positive or negative modulators, but by context-sensitive networks in which the same molecule may exert divergent effects depending on the surrounding cellular environment.

Epigenetic programming of context-dependent responses

Epigenetic regulation represents a critical, but often underappreciated, layer of NLRP3 control that helps explain why similar upstream stimuli can generate distinct functional outcomes. Chromatin accessibility at the NLRP3 locus, as well as at genes encoding inflammasome components and downstream cytokines, influences both the magnitude and kinetics of NLRP3 responses [23, 24]. For example, tissue-resident macrophages differ epigenetically from circulating monocytes, and tissue-specific transcription factors such as PPARG in adipose tissue and RUNX3 in the intestine may help establish open chromatin states that permit rapid induction of NLRP3 and IL1B upon stimulation [46, 47]. By contrast, regulatory dendritic cell subsets may retain repressive histone marks, including H3K27me3 and H3K9me3, at inflammatory loci, thereby limiting inflammasome-related gene expression and supporting a tolerogenic phenotype. Importantly, these epigenetic states are not static, but can be remodeled by environmental signals, providing a plausible mechanism for adaptive plasticity in NLRP3 function.

DNA methylation provides an additional mechanism for context-dependent regulation. DNA methylation may also contribute to context-dependent regulation of IL1B expression in intestinal inflammatory states. This repressive state may also be reversible. Acute inflammatory cues may recruit DNA demethylating enzymes, including TET family proteins, restore IL1B transcriptional competence, and permit rapid IL-1β production when needed. Conversely, prolonged exposure to anti-inflammatory signals such as IL-10 and TGF-β may reinforce repressive epigenetic programs and sustain IL-1β suppression. Histone acetylation adds a further layer of regulation: depending on dose and cellular context, histone deacetylase inhibitors have been reported to either enhance or suppress NLRP3 activation, likely reflecting acetylation-dependent effects on distinct regulatory elements or non-histone proteins involved in inflammatory signaling [48, 49].

Together, these observations suggest that epigenetic programming, established during cell differentiation and continuously modified by local environmental cues, conditions how cells respond to NLRP3 activation. A useful conceptual framework is to distinguish between an “activation-competent” state and a more restrained or “tolerized” state. In the former, open chromatin at NLRP3-, IL1B-, and inflammasome-associated loci permits rapid and robust inflammatory responses, often favoring IL-1β-dominant output and pyroptotic signaling. In the latter, repressive chromatin architecture and inhibitory regulatory programs limit excessive activation and may favor more selective responses, including relative preservation of IL-18-associated functions or inflammasome-independent activities (Fig. 1) [50, 51].

Fig. 1.

Mechanistic dichotomy and epigenetic governance of NLRP3 inflammasome outcomes. The figure illustrates how epigenetic state and regulatory inputs shape divergent NLRP3 outputs. An activation-competent state with open chromatin and strong NF-κB priming favors pro-IL-1β expression, caspase-1 activation, GSDMD cleavage, and pyroptosis, leading to IL-1β-dominant inflammatory responses. By contrast, a restrained state with repressive chromatin and relative pro-IL-1β silencing favors IL-18-dominant signaling, ESCRT-dependent membrane repair, and cell survival or hyperactivation. Caspase-8, BRCC3, and MARCH7 are shown as representative regulators of this context-dependent switch

Context-dependent functional outcomes in diseases

Cellul\ar context: cell type-specific NLRP3 functions

A major source of context dependence in NLRP3 biology is cellular identity. Even when exposed to similar upstream stimuli, different cell types can generate distinct inflammasome outputs because they differ in basal priming state, epigenetic configuration, death-pathway susceptibility, and cytokine-processing capacity. As a result, NLRP3 activation should not be viewed as a uniform response program, but rather as a cell type-specific signaling module whose consequences vary across myeloid and non-myeloid compartments (Fig. 2; Table 1).

Fig. 2.

Spatiotemporal plasticity of the NLRP3 inflammasome across disease contexts. (A) In cancer, NLRP3 function shifts from a protective role in early tumorigenesis, characterized by pyroptotic elimination of premalignant cells and IL-18-associated epithelial repair, to a pathogenic role in established tumors, where IL-1β-dominant signaling promotes immunosuppression, angiogenesis, epithelial–mesenchymal transition, and metastasis. (B) In inflammatory bowel disease, NLRP3 function is state-dependent: IL-18-dominant signaling supports barrier protection during chronic or homeostatic phases, whereas IL-1β-dominant signaling during acute flares promotes neutrophil recruitment and mucosal damage. (C) In autoimmunity, NLRP3 function is compartment-dependent: proposed NLRP3-related tolerogenic dendritic-cell signaling may support immune tolerance in selected experimental contexts, whereas inflammasome activation at peripheral effector sites promotes IL-1β-driven pathogenic inflammation

Table 1.

Context-dependent functional roles of NLRP3 inflammasome across diseases

Disease	Stage / Context	NLRP3 Role	Dominant Cytokine	Key Mechanism	Ref.
Cancer (CAC)	Early stage / tumor initiation	Protective	IL-18	NLRP3-driven pyroptosis eliminates premalignant cells; IL-18 maintains mucosal barrier and promotes epithelial repair	[52, 53]
Cancer (solid tumors)	Advanced stage / established TME	Pathogenic	IL-1β	TAM-derived IL-1β creates immunosuppressive TME; promotes MDSC expansion, Treg induction, angiogenesis (VEGF), and EMT	[21, 54, 55]
IBD	Remission / chronic phase	Protective	IL-18	Tonic IL-18 from lamina propria macrophages and IECs maintains tight-junction integrity, mucin secretion, and antimicrobial peptide output	[56–58]
IBD	Acute inflammatory flare	Pathogenic	IL-1β	Priming signals (LPS, TNF-α) upregulate pro-IL-1β in infiltrating monocytes → neutrophil recruitment, Th17 amplification, mucosal destruction	[59, 60]
Rheumatoid arthritis	Active synovitis	Pathogenic	IL-1β	Synovial macrophage NLRP3 → IL-1β drives cartilage destruction, bone erosion, and Th17-mediated inflammation	[61, 62]
Systemic lupus erythematosus	Tolerance phase	Protective*	IL-18 / TGF-β	Proposed NLRP3-related tolerogenic DC program involving PD-L1 and TGF-β signaling; mainly supported by murine data	[51, 63]
SLE	Flare / inflammasome hyperactivation	Pathogenic	IL-1β	Type-I IFN drives unconventional IL-1β secretion in monocytes; amplifies autoantibody-mediated damage	[64]
Atherosclerosis	Chronic / plaque progression	Pathogenic	IL-1β	Cholesterol crystals activate NLRP3 → IL-1β promotes vascular inflammation, plaque instability	[65]
Type 2 Diabetes	Chronic hyperglycemia / β-cell stress	Pathogenic	IL-1β	Islet amyloid polypeptide (IAPP) and fatty acids activate NLRP3 → IL-1β impairs insulin signaling and promotes β-cell loss	[65, 66]
Acute bacterial / viral infection	Active pathogen challenge	Protective	IL-1β + IL-18	Pyroptosis eliminates intracellular pathogen niche; IL-1β recruits neutrophils; IL-18 drives IFN-γ/Th1 for intracellular pathogen control	[11– [13, 37, 38]

*Protective roles related to immune tolerance in SLE are hypothesis-generating and require validation in human primary tissues or patient-derived systems

Abbreviations: CAC, colitis-associated cancer; TME, tumor microenvironment; TAM, tumor-associated macrophage; MDSC, myeloid-derived suppressor cell; EMT, epithelial–mesenchymal transition; IBD, inflammatory bowel disease; IEC, intestinal epithelial cell; SLE, systemic lupus erythematosus; DC, dendritic cell; IAPP, islet amyloid polypeptide; IFN-γ, interferon-γ

Macrophages: canonical inflammatory and pyroptotic responses

Macrophages represent the best-characterized cellular context for NLRP3 activation. In these cells, inflammasome activation typically leads to robust caspase-1 activation, efficient processing of IL-1β and IL-18, and GSDMD-dependent pyroptotic cell death [20, 67]. This canonical response is particularly important in infection, where pyroptosis can eliminate intracellular pathogen niches while simultaneously releasing inflammatory mediators that recruit and activate additional immune cells [21, 68]. However, macrophage responses are not uniform. Tissue-resident macrophages, such as alveolar macrophages and Kupffer cells, may exhibit distinct NLRP3 response profiles compared with recruited inflammatory macrophages, likely reflecting differences in tissue-specific homeostatic programming and epigenetic state [54, 69, 70]. Thus, even within the macrophage lineage, NLRP3 output is shaped by cellular specialization and local tissue adaptation.

Dendritic cells: inflammasome signaling under tolerogenic constraint

Compared with macrophages, dendritic cells generally display a more restrained pattern of NLRP3 activation, consistent with their dual role in initiating adaptive immunity while preserving peripheral tolerance [14, 42]. In these cells, regulatory mechanisms including caspase-8-dependent control can limit excessive inflammasome activation and prevent inflammatory responses that would impair antigen presentation, migration, or tolerogenic function [25, 44]. When activated by strong danger signals, NLRP3 in dendritic cells may promote maturation and immune activation, but this response is usually more tightly controlled than in macrophages [22]. In addition, certain dendritic cell subsets, including plasmacytoid or regulatory populations, appear to maintain low inflammasome responsiveness through epigenetic repression of inflammatory programs. This restraint is biologically important, because uncontrolled NLRP3 activation in dendritic cells has been linked to loss of immune tolerance and promotion of autoimmunity.

Neutrophils: alternative cell-death and effector programs

Unlike macrophages, in which NLRP3 activation typically culminates in caspase-1-dependent cytokine maturation and GSDMD-mediated pyroptosis, neutrophils often engage alternative effector programs, particularly NETosis, and may rely on non-canonical caspase pathways depending on the stimulus. Inflammasome-related activation in neutrophils is often associated with NETosis, a process involving release of chromatin and granule proteins into the extracellular space [48, 49]. In some settings, this response depends on GSDMD cleavage mediated by caspase-11 in mice or caspase-4/5 in humans, rather than by canonical caspase-1 signaling alone [36]. NET formation can contribute to host defense by trapping extracellular pathogens, but excessive NETosis may also drive collateral tissue damage and immunothrombosis, particularly in sepsis and chronic inflammatory disease [27]. These features distinguish neutrophil NLRP3 biology from that of macrophages and reinforce the principle that the functional consequences of inflammasome activation depend strongly on cellular context.

Non-immune cells: controversial and potentially non-canonical functions

NLRP3 activity in non-immune cells, including epithelial, endothelial, and fibroblast populations, has been reported or proposed in several disease contexts, but these findings should be considered provisional because the evidence remains technically challenging to interpret. In intestinal epithelial cells, NLRP3 has been implicated in barrier maintenance, potentially through IL-18-associated effects or non-canonical mechanisms. In renal and pulmonary fibroblast populations, NLRP3 has been reported to promote fibrosis by supporting TGF-β receptor signaling, enhancing SMAD activation, and driving profibrotic gene expression independently of classical caspase-1-mediated inflammasome assembly [67, 71]. However, apparent NLRP3 signals in non-immune compartments may reflect contamination by infiltrating myeloid cells, including macrophages, monocytes, neutrophils, or dendritic cells, rather than bona fide cell-intrinsic expression or activity.

Therefore, claims of autonomous NLRP3 activity in non-immune cells require stringent validation. Recommended approaches include analysis of highly purified cell populations; exclusion of CD45/PTPRC-positive immune cells and myeloid markers such as ITGAM, LYZ, CSF1R, and CD68; confirmation of lineage-specific markers such as EPCAM for epithelial cells, PECAM1 or VWF for endothelial cells, and COL1A1, PDGFRB, or ACTA2 for fibroblast/stromal populations; and integration of single-cell or single-nucleus RNA sequencing with spatially resolved validation. Cell type-specific genetic perturbation, lineage-restricted assays, and protein-level detection using validated antibodies or in situ approaches will also be necessary to determine whether observed phenotypes truly arise from intrinsic NLRP3 activity in non-immune compartments. Until such evidence is available, non-immune-cell NLRP3 should be treated as a proposed mechanism requiring context-specific validation rather than an established autonomous pathway.

Microenvironmental context: infectious versus sterile inflammation

In addition to cellular identity, the surrounding tissue environment is a major determinant of NLRP3 function. The same inflammasome machinery may support host defense in one setting yet promote chronic tissue injury in another, depending on whether activation occurs in the context of infection, sterile damage, or a metabolically and immunologically altered tissue niche. Thus, microenvironmental context is a key layer linking upstream triggers to divergent biological outcomes.

Protective functions during infection

During infection, NLRP3 activation generally contributes to host defense. Diverse pathogens can activate NLRP3 through distinct upstream mechanisms, including pore-forming toxins that disrupt ion homeostasis, microbial nucleic acids that engage intracellular sensing pathways, and phagocytosed organisms that induce lysosomal damage. Once activated, the inflammasome promotes IL-1β production, which supports fever, neutrophil recruitment, and amplification of local inflammatory responses, while IL-18 acts together with IL-12 to stimulate interferon-γ production and strengthen immunity against intracellular pathogens. In parallel, pyroptotic death of infected macrophages may eliminate intracellular replication niches and release danger signals that alert neighboring immune cells. Consistent with these protective functions, genetic studies in mice have shown that NLRP3 deficiency increases susceptibility to bacterial, viral, and fungal infection [37, 38]. In this context, NLRP3 acts primarily as a host-protective sensor that coordinates pathogen clearance and acute inflammatory containment.

Pathogenic functions during sterile inflammation

By contrast, chronic NLRP3 activation in sterile inflammatory settings often becomes maladaptive. In these conditions, the activating stimuli are not pathogens but endogenous danger-associated signals or accumulated metabolic products, including cholesterol crystals in atherosclerosis, islet amyloid in type 2 diabetes, and saturated fatty acids in obesity [65, 66, 72]. Unlike acute infection, where inflammasome activation is typically self-limited after pathogen clearance, sterile inflammation is often sustained by continuous exposure to damage-associated molecular patterns and metabolic stress. This persistent activation favors prolonged IL-1β-driven inflammation, contributing to vascular injury, insulin resistance, and broader metabolic dysfunction. In such settings, the host-protective antimicrobial benefits of inflammasome activation are reduced, whereas the tissue-damaging consequences of chronic inflammatory signaling become dominant. The transition from infectious to sterile activation therefore represents a major shift in the functional valence of NLRP3 signaling—from protective immune defense to chronic pathological amplification [73].

The role of tissue microenvironment signals

Beyond the broad distinction between infection and sterile inflammation, local tissue signals further shape NLRP3 output. Hypoxia, which is common in inflamed tissues and tumor microenvironments, may either enhance or constrain inflammasome activity depending on duration and severity: acute hypoxia can promote NLRP3 activation through HIF-1α-dependent pathways, whereas prolonged or severe hypoxia may suppress inflammasome function by limiting cellular energy availability [74, 75]. Metabolic conditions also influence NLRP3 responsiveness. Glucose-rich environments can enhance activation by increasing mitochondrial reactive oxygen species, whereas ketone bodies such as β-hydroxybutyrate have been reported to inhibit NLRP3 directly [76]. In addition, local anti-inflammatory cytokines, particularly IL-10 and TGF-β, can restrain inflammasome signaling through transcriptional suppression and induction of negative regulatory programs [29, 77]. These observations indicate that NLRP3 function is not determined solely by the initiating stimulus, but also by the broader metabolic, hypoxic, and cytokine environment in which activation occurs. Together, these tissue-specific signals help explain why similar inflammasome activation may resolve acute injury in one setting yet sustain chronic pathology in another.

Disease-specific contexts: stage-dependent functional shifts

Cancer: from tumor suppression to tumor promotion

Cancer provides one of the clearest examples of context-dependent functional inversion in NLRP3 biology. In early tumorigenesis, particularly in inflammation-associated settings such as colitis-associated cancer (CAC), NLRP3 may exert tumor-suppressive effects [52]. Mechanistically, NLRP3-driven pyroptosis can eliminate premalignant cells before clonal expansion, while IL-18 produced within the intestinal microenvironment may help maintain epithelial barrier integrity, promote mucosal repair, and reduce the accumulation of mutation-promoting inflammatory damage. Consistent with this view, NLRP3-deficient mice develop larger tumor burdens in experimental models of colitis-associated carcinogenesis, supporting a protective role during early disease [53].

By contrast, in established solid tumors, NLRP3 signaling is more often associated with tumor-promoting effects [21, 54, 55]. In these settings, chronic inflammasome activation within tumor-associated macrophages and, in some reports, within tumor cells themselves, can drive IL-1β-dominant inflammatory signaling that supports an immunosuppressive and pro-metastatic microenvironment. This includes expansion of myeloid-derived suppressor cells, enhancement of regulatory T-cell activity, induction of pro-angiogenic programs such as VEGF signaling, and promotion of epithelial-mesenchymal transition. Clinical observations are broadly consistent with this pathogenic role: elevated IL-1β in tumor tissue or circulation has been associated with poor prognosis in several cancers, and preclinical studies suggest that inhibition of NLRP3 or IL-1β may reduce metastasis and improve responses to immune checkpoint blockade [78, 79].

Taken together, current evidence suggests that the role of NLRP3 in cancer depends strongly on both disease stage and cellular source. In early inflammatory tumor initiation, NLRP3 may function as a gatekeeper that promotes epithelial integrity and removes damaged or premalignant cells. However, once tumors become established, chronic activation of the NLRP3 axis within the tumor microenvironment may shift signaling toward sustained IL-1β-driven inflammation, thereby supporting immune evasion, stromal remodeling, and tumor progression. This apparent functional inversion likely reflects a broader change in biological context, including altered tissue architecture, hypoxia, necrosis, metabolic stress, and the accumulation of immunosuppressive myeloid populations within the tumor niche.

Despite this attractive framework, important limitations remain. Evidence for protective early-stage effects is strongest in murine CAC models, particularly AOM/DSS systems, but these models do not fully recapitulate the genetic and evolutionary complexity of human carcinogenesis driven by alterations in genes such as TP53 or APC [80]. In human cancer, most available evidence remains correlative: high IL-1β expression is associated with poor outcome, but direct causal attribution to NLRP3 activity is often lacking [81]. In addition, apparently conflicting reports in cancers such as lung cancer may reflect differences in tumor subtype, disease stage, and, critically, cellular attribution. Single-cell analyses suggest that signals interpreted as “tumor NLRP3” may in some cases predominantly arise from infiltrating macrophages rather than malignant epithelial cells [82].

A major unresolved question is what drives the transition from IL-18-associated tumor surveillance to IL-1β-dominant immune evasion. Proposed mechanisms include hypoxia-driven HIF-1α reprogramming, epigenetic shifts in tumor-associated macrophages, and lactate-associated metabolic polarization toward immunosuppressive states, but direct causal validation remains limited [83, 84]. This uncertainty has direct therapeutic implications. If NLRP3 is protective during early tumor surveillance but pathogenic in advanced disease, then the timing of intervention becomes critical. Current clinical strategies mostly focus on advanced or metastatic settings, where inhibition is more likely to be beneficial, whereas perioperative or adjuvant settings remain largely unexplored because of concern that premature blockade could impair immune surveillance of residual disease [85]. Future work should therefore prioritize single-cell and spatial profiling across tumor evolution, functional validation in organoid and xenograft systems, and biomarker-informed longitudinal validation studies to define the point at which NLRP3 shifts from a protective to a pathogenic regulator. Only then will context-selective targeting in oncology become biologically and clinically rational [82, 86, 87].

Inflammatory bowel disease: acute damage versus chronic protection

Inflammatory bowel disease (IBD) provides a representative example of context-dependent NLRP3 function, in which disease outcome is shaped less by a simple on/off effect and more by the balance between protective IL-18-associated barrier support and pathogenic IL-1β-driven inflammation [30, 49]. Current evidence suggests that the NLRP3/IL-18 axis is important for maintenance of intestinal homeostasis, whereas excessive IL-1β production during acute inflammatory flares can aggravate mucosal injury.

In experimental models, NLRP3 deficiency is associated with more severe colitis, increased mortality, greater histopathological damage, enhanced bacterial translocation, and delayed mucosal healing, supporting an overall protective role for basal NLRP3 signaling in the intestine [57, 58]. Much of this protection appears to be mediated through IL-18, which promotes intestinal epithelial cell proliferation, supports wound repair, enhances mucin production, stimulates antimicrobial peptide expression, and helps maintain tight-junction integrity [56]. The cellular source of IL-18 is likely to be important in this context. Intestinal lamina propria macrophages may provide tonic IL-18 release under conditions of controlled NLRP3 activation, whereas epithelial cells can generate more localized IL-18-dependent repair responses during mucosal injury [88, 89]. This compartmentalized pattern of activation may allow barrier repair without provoking excessive systemic inflammation.

By contrast, when IL-1β becomes the dominant inflammasome output, particularly during acute disease exacerbations, NLRP3 activation may shift toward a pathogenic role. Strong priming signals derived from bacterial products or inflammatory cytokines increase pro-IL-1β transcription in infiltrating monocytes and activated macrophages, thereby biasing inflammasome signaling toward IL-1β production [90]. In turn, IL-1β promotes neutrophil recruitment, amplifies Th17-associated inflammation, and sustains tissue-destructive immune responses [59, 91]. In DSS-induced acute colitis models, inhibition of IL-1β or NLRP3 during the active inflammatory phase can reduce mucosal injury and inflammatory infiltration [59]. However, prolonged inhibition may become detrimental during the recovery phase, when IL-18-dependent repair mechanisms are likely to be required [60]. These findings suggest that the biological effect of NLRP3 in IBD depends not only on activation itself, but on the timing, intensity, and cytokine profile of that activation.

Several mechanisms may underlie this shift between IL-18-dominant protective signaling and IL-1β-dominant pathogenic signaling. First, pro-IL-1β is highly dependent on NF-κB-mediated priming, whereas pro-IL-18 is constitutively expressed in many intestinal cell populations [92]. Second, epigenetic regulation may also contribute to this shift by suppressing IL1B transcription while preserving barrier-supportive signaling. Third, the magnitude and duration of caspase-1 activation may also influence substrate processing, such that modest activation preferentially supports IL-18 release, whereas sustained and robust activation more efficiently drives IL-1β maturation [93]. Together, these mechanisms provide a plausible explanation for why NLRP3 may support intestinal homeostasis in one context yet worsen inflammation in another.

This framework has direct translational implications. Human IBD is heterogeneous, and at least part of this heterogeneity may reflect differences in IL-1β versus IL-18 predominance. Patients with high fecal or serum IL-1β may represent a subgroup more likely to benefit from IL-1β-targeted intervention [94], whereas other patients may exhibit impaired barrier-supportive signaling that could argue against indiscriminate upstream inhibition. Accordingly, NLRP3-targeted therapy in IBD may need to be context-selective rather than continuous. A plausible strategy would be short-term IL-1β antagonism during acute flares, followed by treatment withdrawal during remission to avoid impairing IL-18-dependent mucosal maintenance, or combination approaches designed to suppress IL-1β while preserving barrier-supportive pathways [56, 95].

Despite the appeal of the IL-1β/IL-18 model, several uncertainties remain. The precise cellular sources of protective IL-18 in human IBD are still incompletely defined, and the relative contributions of epithelial cells, macrophages, and other immune populations require clarification [56]. In addition, conventional clinical classifications such as Crohn’s disease versus ulcerative colitis may not adequately capture the underlying inflammasome-related endotypes; some patients may be flare-prone and IL-1β-high, whereas others may be characterized by impaired NLRP3/IL-18-associated barrier maintenance [96]. The mechanisms that drive the transition from IL-18-dominant to IL-1β-dominant macrophage responses are also not fully resolved, although microbiota-derived metabolites, hypoxia, and metabolic reprogramming have all been proposed [97, 98]. Future progress will likely require biomarker-informed prospective validation studies, spatially resolved tissue profiling, and patient-derived organoid systems capable of modeling how local inflammatory and metabolic cues shape the IL-1β/IL-18 balance [99].

Autoimmune diseases: inflammation versus tolerance

Autoimmune disease provides another setting in which NLRP3 exerts context-dependent and sometimes opposing functions. In some disorders, particularly Th1/Th17-driven conditions such as rheumatoid arthritis (RA) and experimental autoimmune encephalomyelitis (EAE), NLRP3 signaling is predominantly associated with pathogenic inflammation [68, 100]. In RA, synovial macrophages express high levels of NLRP3 and produce IL-1β, thereby promoting cartilage destruction, bone erosion, and pain. Clinical evidence is broadly consistent with this pro-inflammatory role, as IL-1-targeted therapies such as anakinra and canakinumab can reduce disease activity, especially in patients with high baseline IL-1β signaling [61, 62].

However, NLRP3 does not appear to be uniformly pathogenic across all autoimmune settings. In some lupus-like murine models, deficiency of NLRP3 or caspase-1 accelerates disease onset and severity, suggesting that inflammasome-related pathways may contribute to immune regulation under selected experimental conditions. Importantly, these findings should be interpreted as hypothesis-generating evidence rather than as established mechanisms in human autoimmune disease. Proposed mechanisms include maintenance of tolerogenic dendritic-cell programs and support of regulatory T-cell stability. In this framework, loss of NLRP3 signaling may impair expression of co-inhibitory molecules such as PD-L1 and PD-L2, reduce TGF-β-associated tolerogenic signaling, and facilitate self-reactive T-cell activation [51, 63]. However, these tolerance-related mechanisms remain largely model-derived and require validation in human primary tissues and patient-derived systems. Human systemic lupus erythematosus (SLE) is also heterogeneous, with some patients showing inflammasome hyperactivation associated with flares and others displaying immune profiles that may be more consistent with defective clearance or impaired regulatory programs [48, 101]. Nevertheless, whether the protective NLRP3-related tolerance mechanisms observed in murine models operate in human SLE or other autoimmune diseases remains uncertain. This uncertainty complicates therapeutic interpretation, because a strategy that benefits IL-1β-driven tissue inflammation may not be equally appropriate in antibody-mediated disease characterized by defective immune regulation.

Taken together, these observations suggest that the role of NLRP3 in autoimmunity depends heavily on both disease mechanism and cellular compartment. When NLRP3 is activated in tissue effector cells at sites of inflammation, such as synovial macrophages or CNS-associated myeloid cells, it may amplify local injury. By contrast, when NLRP3-related pathways operate within antigen-presenting or regulatory immune compartments, they may contribute to maintenance of tolerance and limitation of autoreactivity. The apparent contrast between RA/EAE and selected lupus-like contexts therefore likely reflects differences in dominant immune circuitry rather than a simple disease-specific inconsistency. However, this framework should currently be viewed as a candidate immune-endotype hypothesis rather than a validated basis for clinical stratification. If these tolerance-related mechanisms are confirmed in human primary tissues and patient-derived systems, they may help refine future patient stratification according to immune endotype, tissue compartment, and cytokine profile. Until such validation is available, they should not be used as stand-alone criteria for patient stratification or therapeutic selection.

Despite this emerging framework, major uncertainties remain. In Th1/Th17-dominant disease such as RA, the clinical rationale for IL-1-directed intervention is relatively strong, but the modest responder rate suggests substantial underlying heterogeneity that is still not adequately captured by current biomarkers [102, 103]. In SLE, both animal and human studies indicate variable NLRP3 involvement depending on genetic background, disease trigger, and immune phenotype, raising the possibility that different patient subsets may require different therapeutic strategies [104, 105]. Moreover, the proposed protective role of NLRP3 in tolerance maintenance remains supported largely by murine data, and direct validation in human autoimmune disease is limited [106, 107]. Therefore, this protective tolerance-related role should be considered provisional and should be further tested in human primary tissues, patient-derived immune cells, and functional ex vivo systems before being incorporated into patient stratification or therapeutic decision-making.

Therapeutic interpretation is further complicated by the dual nature of IL-18. Although selective IL-1β blockade may preserve potentially beneficial IL-18 signaling, IL-18 can also amplify Th1-associated inflammation under certain conditions, particularly through synergy with IL-12 and interferon-γ pathways [107]. Therefore, prospective stratification should currently be regarded as a research priority rather than an established clinical tool. Future studies should determine whether patients with IL-1β-dominant inflammatory profiles differ from those with impaired regulatory or tolerance-associated programs, and whether these patterns predict response to NLRP3 or IL-1-targeted intervention. Candidate approaches include combined immune profiling, tissue-level assessment of inflammasome activation, and baseline cytokine-ratio analysis, but these strategies require prospective validation in disease-specific cohorts before they can inform therapeutic decisions [108, 109]. Future work should also prioritize responder-versus-nonresponder immunophenotyping and patient-derived functional assays that define individualized NLRP3 response patterns. Any strategy aimed at restoring, rather than inhibiting, selected NLRP3-related pathways should be considered experimental until protective tolerance-associated mechanisms are validated in human autoimmune systems [110, 111].

Clinical validation: IL-1β blockade in chronic inflammation

Therapeutic targeting of the NLRP3–IL-1β axis has progressed from preclinical rationale to clinical validation, particularly in chronic inflammatory disorders (Table 2). The clearest example is the CANTOS trial, which established the clinical relevance of IL-1β-driven inflammation in atherosclerosis. In that study, canakinumab significantly reduced recurrent cardiovascular events in patients with prior myocardial infarction and elevated high-sensitivity C-reactive protein, thereby providing proof of concept that selective cytokine blockade can improve outcomes in inflammation-associated disease [78]. Importantly, greater benefit was observed in patients who achieved stronger suppression of inflammatory biomarkers during treatment, suggesting that biomarker-informed enrichment may improve therapeutic precision.

Table 2.

Selected clinical and translational evidence targeting the NLRP3–IL-1β axis

Agent	Target	Disease	Trial / Study	Subjects	Key Outcome	Ref.
Canakinumab (anti-IL-1β mAb)	IL-1β	Atherosclerosis / post-MI	CANTOS (Phase III)	n = 10,061	Reduced recurrent MACE in patients with prior myocardial infarction and elevated hsCRP; benefit associated with on-treatment inflammatory suppression	[78]
Anakinra (IL-1Ra)	IL-1R	Rheumatoid arthritis	Cochrane meta-analysis	Multiple RCTs	Reduced disease activity in rheumatoid arthritis, with variable response across patients	[61, 62]
MCC950 (small molecule)	NLRP3	Multiple preclinical indications	Preclinical studies	Animal models	Demonstrated efficacy across several inflammatory disease models, supporting proof of concept for direct NLRP3 inhibition	[28]
NLRP3-selective inhibitors (class)	NLRP3	Multiple inflammatory indications	Early clinical development	Ongoing	Active area of translational development; long-term efficacy, safety, and disease selectivity remain unresolved	[28, 112]

Abbreviations: mAb, monoclonal antibody; IL-1Ra, interleukin-1 receptor antagonist; MACE, major adverse cardiovascular events; MI, myocardial infarction; hsCRP, high-sensitivity C-reactive protein; RCT, randomized controlled trial

The clinical relevance of IL-1β blockade is also evident in autoinflammatory and rheumatic disease. In cryopyrin-associated periodic syndromes (CAPS), where NLRP3 is constitutively activated by gain-of-function mutations, IL-1β blockade often produces rapid and marked clinical benefit. In rheumatoid arthritis, IL-1-targeted therapies such as anakinra can reduce disease activity, although treatment response is heterogeneous and appears to depend on inflammatory context [61, 62]. Taken together, these observations confirm that the NLRP3–IL-1β axis is therapeutically actionable, while also indicating that treatment response is likely shaped by disease mechanism, baseline inflammatory burden, and patient-specific biology.

NLRP3-specific inhibitors: from bench to bedside

Although IL-1β antagonists validate the importance of the pathway, they do not directly inhibit NLRP3 itself and therefore cannot distinguish inflammasome-derived IL-1β from IL-1β generated through other mechanisms. Direct NLRP3 inhibitors offer a different therapeutic strategy, with the theoretical advantages of acting further upstream and potentially influencing inflammasome-dependent processes beyond cytokine release (Table 2) [28]. MCC950 remains the best-characterized small-molecule NLRP3 inhibitor and has shown robust efficacy across multiple preclinical models, including atherosclerosis, heart failure, nonalcoholic steatohepatitis, and neurodegenerative disease. However, its clinical development was limited by hepatotoxicity, underscoring an important translational challenge: broad and sustained inhibition of NLRP3 may reduce pathogenic inflammation, but it may also interfere with protective immune functions or introduce toxicity through excessive pathway suppression.

Newer NLRP3 inhibitors are now being evaluated with the aim of achieving a more favorable balance between efficacy and safety. Oral agents such as dapansutril (OLT1177) have shown acceptable tolerability in early clinical studies, with preliminary evidence of anti-inflammatory activity, while additional selective inhibitors, including IFM-2427/DFV-890, are under investigation in inflammatory disorders and autoinflammatory syndromes. Several compounds with improved CNS penetration are also being developed for neuroinflammatory and neurodegenerative indications. These efforts will help determine whether direct NLRP3 inhibition can provide advantages over downstream cytokine blockade. At the same time, the biology reviewed in earlier sections argues for caution: because direct NLRP3 inhibition may suppress both IL-1β and IL-18, it may be less desirable in disease settings where IL-18 has context-dependent protective functions, such as maintenance of epithelial barrier integrity in selected IBD contexts. In such cases, selective IL-1β blockade may offer a more biologically precise alternative.

Context-selective strategies: matching treatment to disease state

Taken together, current evidence suggests that the therapeutic future of NLRP3 targeting lies not in universal inhibition, but in context-selective intervention. The key translational principle is that treatment should ultimately be matched to disease mechanism, disease stage, dominant cytokine output, and patient-specific inflammatory profile [112]. Several practical strategies emerge from this framework. First, timing matters. In IBD, transient suppression of IL-1β during acute flares may reduce tissue-destructive inflammation, whereas prolonged inhibition during remission could compromise IL-18-dependent barrier maintenance. In cancer, inhibition may be more appropriate in advanced or metastatic settings characterized by chronic IL-1β-driven immunosuppression than in early-stage disease, where inflammasome-related tumor surveillance may still be beneficial. Second, target level matters. Selective IL-1β neutralization may preserve potentially beneficial IL-18 signaling, whereas IL-18-directed intervention, including IL-18 binding protein or anti-IL-18 approaches, may be more appropriate in diseases where IL-18 itself becomes pathogenic, such as macrophage activation syndrome [113, 114].

Third, biomarker-informed stratification will likely be important, but it should currently be developed as a prospectively validated research framework rather than assumed to be a ready clinical tool. The CANTOS experience suggests that inflammatory biomarkers may help enrich for patients more likely to derive benefit from pathway inhibition, but similar approaches in IBD, cancer, and autoimmune disease still require disease-specific assay standardization, threshold definition, and prospective validation before they can guide therapeutic decisions [114]. Fourth, combination strategies may improve precision while reducing risk. In oncology, pairing NLRP3 or IL-1β blockade with immune checkpoint inhibitors may help counteract myeloid-driven immunosuppression while preserving or restoring antitumor T-cell responses. In IBD, combining selective inflammatory suppression with barrier-supportive or microbiome-directed interventions may prove more effective than pathway inhibition alone. More broadly, these approaches reflect a shift from viewing NLRP3 as a uniformly harmful target toward treating it as a context-dependent signaling node whose pathogenic functions should be selectively neutralized while beneficial functions are preserved whenever possible.

Future perspectives and unresolved questions

Evidence limitations and translational boundaries

Several evidence limitations should be considered when interpreting the context-dependent functions of NLRP3. First, proposed roles of NLRP3 in non-immune cells remain incompletely resolved, because apparent cell-intrinsic signals in epithelial, endothelial, or fibroblast populations may be confounded by infiltrating myeloid cells in inflamed or injured tissues [16, 55]. Second, some protective mechanisms discussed in this review, particularly those related to immune tolerance in autoimmune disease, are supported mainly by murine studies and should therefore be regarded as hypothesis-generating rather than clinically established mechanisms in human disease [51, 63, 106]. Third, although biomarker-informed therapeutic development is a promising direction, currently proposed inflammasome-related markers still require standardization, prospective validation, and disease-specific threshold definition before they can reliably guide clinical decisions [28, 29]. These limitations highlight the need to distinguish established evidence from provisional concepts when developing context-selective NLRP3-targeted strategies.

Mechanistic basis of context-dependent switching

Building on these limitations, a central unresolved question is why apparently similar NLRP3 activation can lead to opposite biological outcomes in different settings. Although this review has highlighted downstream manifestations of this divergence, including IL-1β versus IL-18 bias and pyroptosis versus survival, the upstream determinants of these shifts remain incompletely understood. Epigenetic and transcriptional programming likely represent a major regulatory layer. Cell type-specific enhancer architecture, chromatin accessibility, and transcription-factor networks may determine how individual cells interpret and respond to NLRP3 activation. Integrative multi-omic approaches combining transcriptomics, epigenomics, and proteomics may therefore help identify the master regulators that switch NLRP3 function between protective and pathogenic modes [115–117].

Metabolic regulation is another important area for future study. Cellular metabolic state strongly influences inflammasome signaling, with glycolysis, oxidative phosphorylation, NAD+/NADH balance, nutrient availability, and mitochondrial fitness all shaping NLRP3 responsiveness [117]. Context-dependent metabolic reprogramming driven by oxygen tension, nutrient supply, and growth-factor signaling may therefore redirect inflammasome output. For example, metabolic polarization in tumor-associated macrophages may bias NLRP3 signaling toward pro-tumor inflammatory programs [112]. In parallel, post-translational regulation adds another layer of complexity. Differential ubiquitination, phosphorylation, and related protein modifications may encode distinct functional states of the NLRP3 complex. Advanced proteomic strategies, including phosphoproteomics and ubiquitin-chain mapping in disease-specific contexts, may help define these regulatory codes more precisely [118].

Validation of non-canonical functions

The proposed inflammasome-independent and non-immune functions of NLRP3 remain among the most controversial issues in the field and require rigorous validation [16, 55]. Single-cell transcriptomic analyses have raised questions about the consistency and magnitude of NLRP3 expression in epithelial, fibroblast, and neuronal populations, thereby challenging some of the conclusions drawn from earlier functional studies. Resolving this issue will require several complementary approaches: highly specific detection methods, including validated antibodies and in situ assays with strict controls; stringent exclusion of myeloid-cell contamination in non-immune cell preparations; and cell type-specific genetic models capable of testing whether observed phenotypes truly arise from intrinsic NLRP3 activity in non-immune compartments [26, 42].

The answer to this question has important translational implications. If non-immune NLRP3 functions are confirmed, the therapeutic landscape would broaden substantially, including the possibility of targeting scaffold-like or non-canonical NLRP3 functions in fibrosis and tissue remodeling [28]. If these claims are not sustained, therapeutic efforts could focus more narrowly on immune compartments. A similar need for validation applies to proposed nuclear and transcriptional roles of NLRP3. Reports of nuclear localization and gene-regulatory activity remain provocative but incomplete, and would require independent confirmation using approaches such as ChIP-seq, nuclear-localization mutant rescue experiments, and direct demonstration of gene-expression changes attributable to nuclear NLRP3 [29, 119, 120]. If validated, such findings would require a broader reconceptualization of NLRP3 as a multi-compartment signaling protein rather than a purely cytoplasmic inflammasome sensor.

Predictive models and biomarkers

A major unmet need is the ability to predict the dominant functional output of NLRP3 in a given patient and disease context, including whether it is more closely associated with tissue protection, inflammatory amplification, or mixed intermediate states. Such predictive frameworks would be valuable for trial design and therapeutic hypothesis generation, but they should currently be regarded as research tools rather than validated clinical decision systems [26, 42]. Development of these models will likely require multidimensional biomarker panels integrating cytokine balance, markers of inflammasome activation, cellular composition, and disease-specific tissue features. Candidate readouts include IL-1β/IL-18 ratios, ASC specks, cleaved caspase-1, circulating or tissue GSDMD-related signals, and immune-cell profiling of macrophage, dendritic-cell, and neutrophil states [28, 29]. However, none of these markers currently provides a standardized, prospectively validated, stand-alone threshold for defining NLRP3 functional states across diseases. Therefore, biomarker-informed stratification should be developed as a disease-specific and longitudinal validation framework rather than as a universal clinical algorithm.

Defining a clinically interpretable threshold matrix for NLRP3-related biomarkers will require several layers of validation. First, assays must be standardized across platforms, sample types, and time points. Second, blood-based readouts should be paired with tissue-level measurements whenever possible, because circulating cytokines may fluctuate rapidly and may not accurately reflect local inflammasome activity. Third, thresholds should be defined within disease-specific cohorts and stratified by disease stage, tissue compartment, treatment exposure, and clinical outcome. For example, the same IL-1β/IL-18 ratio may have different implications in acute IBD flares, chronic mucosal repair, advanced cancer, or autoimmune disease. Accordingly, cytokine ratios should be interpreted together with ASC specks, GSDMD cleavage, immune-cell composition, and spatial tissue features rather than used as isolated decision markers.

Spatially resolved technologies may be particularly informative in this setting, but they also require careful interpretation. Spatial transcriptomics and multiplex imaging platforms can map NLRP3-associated signals in intact tissue architecture, potentially distinguishing compartmentalized activation from diffuse tissue-damaging inflammasome signaling [119, 120]. However, transcriptomic localization alone cannot fully capture dynamic extracellular events such as ASC speck release or rapid cytokine dissemination. Therefore, spatial approaches should ideally be combined with protein-level detection, multiplex immunostaining, extracellular ASC speck assessment, and functional ex vivo assays using patient-derived cells. Such assays could generate individualized “NLRP3 response profiles” based on cytokine output, cell-death behavior, ASC/GSDMD-related signals, and signaling dynamics under standardized stimulation conditions [121]. Computational approaches, including machine learning, may help integrate these variables, but clinical-grade models will require external validation, calibration across organ systems, and prospective testing before they can inform therapeutic decisions.

Next-generation therapeutic strategies

Future NLRP3-directed therapies should be designed with context selectivity in mind rather than relying on complete and sustained pathway suppression [42]. One attractive possibility is the development of allosteric modulators that dampen excessive activation while preserving basal protective functions. Context-sensitive prodrugs that become activated only within specific tissue environments, such as hypoxic tumors or acidic inflammatory lesions, could provide spatial selectivity. Likewise, cell type-specific delivery systems, including antibody-drug conjugates directed toward pathogenic macrophage subsets, may allow restriction of NLRP3 inhibition to the compartments most responsible for disease propagation [122, 123].

Additional future strategies may involve genetic and microbiome-based approaches. Cell type-restricted gene-editing platforms could, in principle, permit long-term suppression of NLRP3 in selected myeloid populations while sparing regulatory immune compartments [123]. Conversely, in contexts where IL-18 is protective, gene-delivery strategies that preserve or restore IL-18-associated functions might complement or refine upstream inhibition. Microbiome-directed interventions also represent a potentially important frontier, particularly in intestinal disease, where engineered microbes or microbial metabolites might indirectly reshape NLRP3 activity and downstream cytokine balance [124, 125]. Although many of these approaches remain speculative, they reflect a broader therapeutic shift: rather than treating context dependence as an obstacle, future work should use it as a design principle for more precise and biologically informed intervention strategies [126].

Conclusion

NLRP3 is best understood not as a uniformly pathogenic inflammasome, but as a context-dependent signaling platform whose biological effects are shaped by cellular identity, tissue microenvironment, and disease stage. Across this review, three interconnected dimensions emerged as central determinants of functional outcome. First, cellular context influences whether NLRP3 activation leads predominantly to pyroptosis, cytokine release, or non-canonical signaling programs. Second, microenvironmental context, particularly the distinction between infectious and sterile inflammatory settings, alters the overall functional valence of inflammasome activation. Third, disease context determines whether NLRP3 acts primarily as a protective regulator or a pathogenic amplifier, as illustrated by its divergent roles in cancer, inflammatory bowel disease, and autoimmune disease. This framing is consistent with the manuscript’s core argument that similar NLRP3 activation can generate opposite outcomes depending on context [23, 28].

These divergent outcomes are not random, but appear to be organized through several mechanistic decision nodes, including cytokine bias between IL-1β and IL-18, broader inflammasome-related outputs such as GSDMD-mediated pore formation and pyroptotic or sublytic responses, cell-fate choice between pyroptosis and survival, context-sensitive action of regulatory molecules, and epigenetic programming of inflammatory responsiveness. Recognition of these nodes helps explain why the same inflammasome can support host defense, barrier maintenance, tissue repair, or immune tolerance in one setting, yet promote chronic inflammation, immune evasion, or tissue damage in another. As a result, indiscriminate NLRP3 inhibition is unlikely to be optimal across all diseases [25].

The therapeutic implication is therefore clear: future intervention strategies should move beyond universal pathway blockade toward context-selective targeting. Such an approach may include stage-adapted treatment timing, selective cytokine targeting, cell type-restricted delivery, biomarker-informed and prospectively validated patient-stratification frameworks, and rational combination therapy. At the same time, several key challenges remain unresolved, including identification of the molecular determinants that drive context-dependent switching, rigorous validation of non-canonical functions in non-immune cells, and development of predictive models capable of defining context-specific NLRP3 functional states in individual patients [78, 112].

Taken together, the current state of the field supports a conceptual shift: NLRP3 should not be viewed simply as a pro-inflammatory target to be broadly suppressed, but as a context-dependent regulator whose function emerges from the interaction of cell-intrinsic programs, local tissue states, and disease-specific pathways. Recognizing this complexity is not a barrier to therapeutic development; rather, it is the basis for more precise and biologically informed intervention. In this sense, NLRP3 may serve as a broader paradigm for how context-dependent immune regulators should be interpreted and targeted in the era of precision medicine.

Author contributions

S.L. and Y.S conceived the study. S.L., X.L., H.C., and J.H. wrote the initial draft. S.Y. and J.F. contributed to literature analysis and manuscript editing. Y.S supervised the project and revised the manuscript critically for important intellectual content. All authors reviewed and approved the final version.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 82271275), the Applied and Basic Research Program of Liaoning Province (Joint Program, 2022JH2/101500058), and the Outstanding Scientific Fund of Shengjing Hospital.

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.